International Journal of Pharmaceutics 2014-07-01

Preparation and evaluation of ritodrine buccal tablets for rational therapeutic use.

Hiraku Onishi, Kei Yumoto, Osamu Sakata

Index: Int. J. Pharm. 468(1-2) , 207-13, (2014)

Full Text: HTML

Abstract

Ritodrine hydrochloride (RD-HCl) tablets containing alginate (AL) and lactose (LC) with or without microcrystalline cellulose (MC) as excipients were produced as a buccal dosage form. The RD-HCl (2 mg) tablets with AL/LC but no MC swelled and dissolved gradually in the in vitro dissolution test. The tablet showing the fastest dissolution and highest drug release rate, called Tablet A1, was selected as a tablet to show rapid and prolonged absorption. However, in the in vivo buccal absorption test using rats, it could not give a plasma concentration over the human minimal effective level (15 ng/mL). The modified tablet containing AL, LC, MC and RD-HCl (4 mg), named Tablet B/MC, showed better hardness and faster drug release. Tablet B/MC gave a plasma concentration over the human effective level within 15 min, and the plasma concentration was maintained at >15 ng/mL over 4 h. Moreover, the deconvolution analyses demonstrated that a prolonged high absorption rate could be achieved in vivo best with Tablet B/MC. Tablet B/MC improved the pharmacokinetic profile in comparison with Tablet A1 and the solution dosage form. The RD-HCl buccal tablets with AL, LC and MC as excipients are suggested to be possibly useful for the treatment of premature labor.Copyright © 2014 Elsevier B.V. All rights reserved.

Related Compounds

Structure Name/CAS No. Articles
Phosphoric acid Structure Phosphoric acid
CAS:7664-38-2
Magnesium stearate Structure Magnesium stearate
CAS:557-04-0
Urethane Structure Urethane
CAS:51-79-6
Ritodrine hydrochloride Structure Ritodrine hydrochloride
CAS:23239-51-2